Skip to main content

The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World

Publication ,  Conference
Suvannasankha, A; LeBlanc, TW; Correll, JR; Carmichael, C; Gorsh, B; Martin, M; Kitchen, H; Eliason, L; Thursfield, M; Boytsov, N; Lewis, MB ...
Published in: Blood
November 15, 2022

Duke Scholars

Published In

Blood

DOI

EISSN

1528-0020

ISSN

0006-4971

Publication Date

November 15, 2022

Volume

140

Issue

Supplement 1

Start / End Page

13264 / 13266

Publisher

American Society of Hematology

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Suvannasankha, A., LeBlanc, T. W., Correll, J. R., Carmichael, C., Gorsh, B., Martin, M., … Kleinman, D. (2022). The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World. In Blood (Vol. 140, pp. 13264–13266). American Society of Hematology. https://doi.org/10.1182/blood-2022-159637
Suvannasankha, Attaya, Thomas W. LeBlanc, Julia R. Correll, Chloe Carmichael, Boris Gorsh, Mona Martin, Helen Kitchen, et al. “The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World.” In Blood, 140:13264–66. American Society of Hematology, 2022. https://doi.org/10.1182/blood-2022-159637.
Suvannasankha A, LeBlanc TW, Correll JR, Carmichael C, Gorsh B, Martin M, et al. The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World. In: Blood. American Society of Hematology; 2022. p. 13264–6.
Suvannasankha, Attaya, et al. “The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World.” Blood, vol. 140, no. Supplement 1, American Society of Hematology, 2022, pp. 13264–66. Crossref, doi:10.1182/blood-2022-159637.
Suvannasankha A, LeBlanc TW, Correll JR, Carmichael C, Gorsh B, Martin M, Kitchen H, Eliason L, Thursfield M, Boytsov N, Brown Hajdukova E, Lewis MB, Mackay C, Paka P, O’Neill A, Perera S, Naine S, Molinari A, Hanna M, Kleinman D. The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World. Blood. American Society of Hematology; 2022. p. 13264–13266.

Published In

Blood

DOI

EISSN

1528-0020

ISSN

0006-4971

Publication Date

November 15, 2022

Volume

140

Issue

Supplement 1

Start / End Page

13264 / 13266

Publisher

American Society of Hematology

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology